Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Biden’s CUREIT initiative aims to develop a toolbox of technologies to fight cancer, autoimmune disorders and infectious diseases.
A personalized melanoma vaccine enters a Phase III study, while a pancreatic cancer vaccine moves on to Phase II.
Moderna and Merck’s personalized neoantigen vaccine plus checkpoint inhibitor lowered the risk of disease progression after surgery by 44%.
The experimental vaccine trains the immune system to recognize HER2 proteins on breast tumors.
A personalized cancer vaccine plus Keytuda lowered the risk of melanoma coming back after surgery.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.